Ozmosi | Zervimesine Drug Profile
Drug Profile
Using advanced filters...

Zervimesine

Pronounced as: zer-VIM-e-seen

Alternative Names: Zervimesine, ct-1812, ct1812, ct 1812
Clinical Status: Active
Latest Update: 2026-08-10
Latest Update Note: Clinical Trial Update

Product Description

Our lead candidate for AlzheimerÕs disease, CT1812, is designed to displace A_ oligomers from their binding sites and has shown early clinical evidence that it improves biomarkers of the disease and may improve cognition in symptomatic patients. (Sourced from: https://cogrx.com/ct1812-mimics-protective-genetic-mutation/)

Mechanisms of Action: PGRMC1 Antagonist, S2R Antagonist

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: N/A

FDA Designation: *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Company: Cognition
Company Location: Eastern America
Company Founding Year: 2014
Additional Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Zervimesine

Countries in Clinic: Australia, Czech Republic, Netherlands, Spain, United States

Active Clinical Trial Count: 4

Recent & Upcoming Milestones

  • Clinical Outcomes Reported - Cognition presented P2 Alzheimer Disease results on 2026-11-19 for Zervimesine
  • Clinical Outcomes Expected - Cognition announced they will present P2 Alzheimer Disease results in 2H27 for Zervimesine
  • Clinical Trial Start Expected - Cognition announced they will initiate a P3 Lewy Body Dementia trial in 3Q27 for Zervimesine

Highest Development Phases

Phase 2: Alzheimer Disease|Dementia|Early Alzheimer Disease|Lewy Body Dementia|Lewy Body Disease|Mild-Moderate Alzheimer Disease

Trial ID

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Latest Trial Update Date

Data Updated

NCT05531656

COG0203

P2

Active, not recruiting

Alzheimer Disease|Early Alzheimer Disease

2027-05-31

43%

2026-08-11

NCT05225415

COG1201

P2

Completed

Lewy Body Disease|Dementia|Lewy Body Dementia

2024-11-25

45%

2025-05-16

NCT03507790

COG0201

P2

Completed

Alzheimer Disease|Mild-Moderate Alzheimer Disease

2024-05-29

40%

2024-07-23

Primary Completion Date|Primary Endpoints|Study Completion Date

2022-002326-27

Clinical Trial of CT1812 in Mild to Moderate Alzheimer’s Disease

P2

Completed

Alzheimer Disease|Mild-Moderate Alzheimer Disease

2024-05-29

40%

2025-05-06

Primary Completion Date|Study Completion Date|Treatments|Trial Status